Jagsonpal Pharmaceuticals Acquires 85% Stake in Aequitas Healthcare, Targeting Hospital Segment Growth

Jagsonpal Pharmaceuticals Acquires 85% Stake in Aequitas Healthcare, Targeting Hospital Segment Growth​

Gurugram, India | June 29, 2026 - Jagsonpal Pharmaceuticals Limited has announced it has entered into a Share Purchase Agreement (SPA) to acquire an 85% stake in Aequitas Healthcare Private Limited. This strategic acquisition marks Jagsonpal's entry into the hospital segment, giving the company access to institutional networks for its pharmaceutical products.

Aequitas Healthcare Private Limited, established in 2017 and based in Mumbai, is a company that specializes in the sale and distribution of pharmaceutical products to hospitals across India. The proposed acquisition is structured as a cash consideration deal.

The total cost for Jagsonpal Pharmaceuticals to acquire the 85% stake is INR 20.8 Crore. The transaction structure ensures that the current directors of Aequitas will retain a 15% stake in the business. The entire deal is expected to be completed by July 15, 2026.

The move aligns with Jagsonpal's strategic objective of gaining access to the hospital channel and institutional doctor network, which would otherwise require significant time and effort to build organically.

Financial Profile of Aequitas Healthcare Private Limited​

Aequitas has a history operating predominantly in the sales of pharmaceutical products to hospitals over the past eight years. The financial performance of the target company demonstrates consistent revenue generation in the industry.

The operational details and historical turnover for Aequitas are detailed below:


Aequitas’s revenue from operations over the last three fiscal years has been as follows:

Strategic Significance for Jagsonpal​

Manish Gupta, Managing Director at Jagsonpal Pharmaceuticals, commented on the transaction, stating that the acquisition represents a major strategic milestone. He noted that it provides a ready platform to establish a meaningful presence in the hospital segment, which he highlighted as contributing significantly and growing faster within the pharmaceutical industry.

Gupta added that the company strongly believes its established portfolio of brands will benefit from Aequitas's strong institutional relationships, promising sustainable long-term value creation.

Mr. Amrut Medhekar, Chief Operating Officer at Jagsonpal, characterized the transaction as a structural pivot for the company, moving Jagsonpal from a legacy retail prescription focus to an Omnichannel Specialty healthcare business in India.

Shailesh Kamat, Director and largest shareholder of Aequitas, expressed satisfaction with the partnership, noting that they had built a strong hospital business with deep institutional relationships over eight years. He stated that he believes the partnership will unlock new opportunities for employees and stakeholders across the healthcare ecosystem.

JAGSNPHARM Stock Price Movement​

Today, shares of Jagsonpal Pharmaceuticals Limited edged higher to close at ₹230.38, gaining 2.96% in post-market trading. The stock saw a total traded volume of 409,303 shares during the session.